Tags

Type your tag names separated by a space and hit enter

Is diabetes the cost to pay for a greater cardiovascular prevention?
Int J Cardiol 2010; 144(2):309-10IJ

Abstract

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites, including isoprenoid and ubiquinone, normally produced during the process of cholesterol synthesis. We therefore suggest that, if statins are prescribed, patients should be monitored closely for blood glucose control even though the higher incidence of diabetes by statin therapy may represent a rare finding.

Pub Type(s)

Letter

Language

eng

PubMed ID

19297038

Citation

Rizzo, Manfredi, et al. "Is Diabetes the Cost to Pay for a Greater Cardiovascular Prevention?" International Journal of Cardiology, vol. 144, no. 2, 2010, pp. 309-10.
Rizzo M, Spinas GA, Rini GB, et al. Is diabetes the cost to pay for a greater cardiovascular prevention? Int J Cardiol. 2010;144(2):309-10.
Rizzo, M., Spinas, G. A., Rini, G. B., & Berneis, K. (2010). Is diabetes the cost to pay for a greater cardiovascular prevention? International Journal of Cardiology, 144(2), pp. 309-10. doi:10.1016/j.ijcard.2009.03.001.
Rizzo M, et al. Is Diabetes the Cost to Pay for a Greater Cardiovascular Prevention. Int J Cardiol. 2010 Oct 8;144(2):309-10. PubMed PMID: 19297038.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is diabetes the cost to pay for a greater cardiovascular prevention? AU - Rizzo,Manfredi, AU - Spinas,Giatgen A, AU - Rini,Giovam Battista, AU - Berneis,Kaspar, Y1 - 2009/03/17/ PY - 2009/02/05/received PY - 2009/03/01/accepted PY - 2009/3/20/entrez PY - 2009/3/20/pubmed PY - 2011/2/2/medline SP - 309 EP - 10 JF - International journal of cardiology JO - Int. J. Cardiol. VL - 144 IS - 2 N2 - The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites, including isoprenoid and ubiquinone, normally produced during the process of cholesterol synthesis. We therefore suggest that, if statins are prescribed, patients should be monitored closely for blood glucose control even though the higher incidence of diabetes by statin therapy may represent a rare finding. SN - 1874-1754 UR - https://www.unboundmedicine.com/medline/citation/19297038/Is_diabetes_the_cost_to_pay_for_a_greater_cardiovascular_prevention L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-5273(09)00242-3 DB - PRIME DP - Unbound Medicine ER -